Medicine and Dentistry
Multiple Myeloma
100%
Adult T-Cell Leukemia/Lymphoma
97%
Infection
72%
Overall Survival
63%
Myelodysplastic Syndrome
56%
Stem Cell Therapy
52%
Human T-Lymphotropic Virus 1
51%
Malignant Neoplasm
50%
COVID-19
48%
Large-Cell Lymphoma
48%
Surveillance, Epidemiology, and End Results
41%
Stem Cell Transplant
36%
Disease
34%
Prevalence
32%
Myelofibrosis
31%
Transplantation
31%
Multivariate Analysis
29%
Lenalidomide
29%
Chimeric Antigen Receptor T-Cell Immunotherapy
26%
Allogeneic Stem Cell Transplantation
26%
Myeloid Malignancy
24%
Activin Receptor
24%
Cohort Effect
24%
T Cell
24%
Interleukin 1 Receptor Associated Kinase 4
24%
Clinical Trial
24%
Hematopoietic Stem Cell
24%
Thoracic Cancer
24%
Leukocyte
24%
Cyanobacterial Toxin
24%
Microcystin
24%
Computer Assisted Tomography
24%
Infectious Complication
24%
Matched Donor
24%
Cell Therapy
24%
Acute Heart Infarction
24%
Cell Transplantation
24%
Eltrombopag
24%
Clostridium Difficile Infection
24%
Chimeric Antigen Receptor T-Cell
24%
Chimeric Antigen Receptor T-Cell Therapy
24%
Vitamin D
24%
Liver Cirrhosis
24%
Percutaneous Coronary Intervention
24%
Brain Ischemia
24%
CAR T-cell therapy
24%
Cancer of Unknown Primary Origin
24%
Progression Free Survival
23%
Telehealth
19%
ST Segment Elevation Myocardial Infarction
19%
Keyphrases
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
68%
United States
65%
Acute Myeloid Leukemia
57%
Hospitalization
51%
Myelodysplastic Syndrome
48%
Multiple Myeloma
48%
Adult T-cell Leukemia
48%
Risk Factors
38%
Autologous SCT
29%
National Trends
29%
Stem Cell Transplantation
27%
Human T-cell Leukemia Virus Type 1 (HTLV-1)
27%
North America
27%
In-hospital Mortality
26%
Overall Survival
26%
Atrial Fibrillation
24%
Janus Kinase 2 (JAK2)
24%
Mucositis
24%
SF3B1 mutation
24%
Large B-cell Lymphoma
24%
Evaluating Risks
24%
Remission
24%
Cystic Fibrosis
24%
Electrical Cardioversion
24%
Enasidenib
24%
CAR-T Treatment
24%
American Adults
24%
CD19 CAR-T
24%
Interleukin-1 Receptor-associated Kinase 4
24%
Inflammatory Immune Response
24%
Survival Trends
24%
Comorbidity
24%
Axicabtagene Ciloleucel
24%
Palifermin
24%
Microcystin
24%
Cyanobacterial Toxins
24%
Venetoclax
24%
Epidemiological Trends
24%
Patients with Cancer
24%
Subnational Analysis
24%
Temporal Trends
24%
Cirrhosis
24%
Pharmacoeconomic Analysis
24%
SEER Analysis
24%
Clostridium Difficile Infection
24%
Ischemic Stroke
24%
CAR T-cell Therapy
24%
Global Longitudinal Strain
24%
Viral Hepatitis
24%
Programmed Death-ligand 1 (PD-L1)
24%
Pharmacology, Toxicology and Pharmaceutical Science
Multiple Myeloma
72%
Overall Survival
52%
Myelodysplastic Syndrome
48%
Large Cell Lymphoma
48%
T Cell Leukemia
48%
Lenalidomide
48%
Disease
38%
Malignant Neoplasm
35%
Human T-Lymphotropic Virus 1
27%
Myeloma
26%
Mucosa Inflammation
24%
Enasidenib
24%
Decitabine
24%
Acute Myeloid Leukemia
24%
Venetoclax
24%
Palifermin
24%
Cyanobacterial Toxin
24%
Vitamin D
24%
Clinical Trial
24%
Infection
24%
Atrial Fibrillation
24%
Pharmacoeconomics
24%
Clostridium Difficile Infection
24%
Eltrombopag
24%
Chimeric Antigen Receptor
24%
Acute Heart Infarction
24%
Myelofibrosis
24%
Toxicity and Intoxication
16%
Cytokine Release Syndrome
16%
B Cell Maturation Antigen
16%
Chemotherapy
16%
Recurrent Disease
16%
Progression Free Survival
15%
Cyanobacteria
14%
Hospital Mortality
10%
ST Segment Elevation Myocardial Infarction
8%
Survival Rate
8%
Remission
8%
Cohort Study
8%
Lactate Dehydrogenase
8%
Immunoglobulin
8%
Disease Exacerbation
8%
Flow Cytometry
8%
HTLV-1 Infection
8%
Thrombocytopenia
7%
Lung Cancer
6%
Ivosidenib
6%
Monotherapy
5%
Observational Study
5%
25 Hydroxyvitamin D
5%